-
-
Call more information
660-596-2224 -
Author: Sophie Eydis Becker’s ASC Review Anesthesia is one of the most emerging threats to ASC profitability. While supply costs, staffing shortages and payer negotiations often dominate executive discussions, anesthesia-related expenses and reimbursement challenges are eroding margins. Here are five things to know about the current state of anesthesiology as it pertains to ASCs: 1. […]
Read MoreAuthor: Ferraro M, et al. Cochrane Database of Systematic Reviews, August 17, 2025. This review examined 67 randomized controlled trials with more than 2300 adults evaluating ketamine, memantine, dextromethorphan, amantadine, and magnesium for chronic noncancer pain. Despite widespread off-label use, there was no convincing evidence that these NMDA receptor agonists reduced pain intensity across short, […]
Read MoreIf you’re an anesthesiologist searching for a balanced lifestyle and rewarding work, you’ll want to check out this opportunity. Our all-anesthesiologist group is seeking a dedicated team member to join our collaborative practice. Position Highlights: Zero Call for 3 Weeks: Enjoy three weeks of no call duty, followed by one week of call. Even during […]
Read MoreWe’re excited to announce the formation of a new anesthesia group in Riverdale, GA, located just 10 minutes from the Atlanta Airport. We’re seeking dedicated CRNAs to join our collaborative care team, which will include 4 full-time CRNAs and 2 anesthesiologists managing 4 operating rooms. This is a 25% independent practice and doing own blocks! […]
Read MoreAuthor: Brauser D Medscape Medical News The FDA has approved KETARx, a racemic ketamine formulation developed by PharmaTher Holdings, for the treatment of post-surgical pain. This marks a significant regulatory milestone for ketamine, which remains the only psychedelic or “psychedelic-adjacent” compound included on the World Health Organization’s list of Essential Medicines. PharmaTher has indicated plans […]
Read More